Background Alzheimer’s disease is characterized by amyloid-beta (Aβ) plaques and
neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to …

Many neurological disorders involve cell death. During development of the nervous system,
cell death is a normal feature. Elimination of substantial numbers of initially generated cells …

The Dementia with Lewy Bodies (DLB) Consortium has refined its recommendations about
the clinical and pathologic diagnosis of DLB, updating the previous report, which has been in …

Background Anti-NMDA receptor (NMDAR) encephalitis is an autoimmune disorder in which
the use of immunotherapy and the long-term outcome have not been defined. We aimed to …

Background: Epidemiologic studies have implicated cerebrovascular disease and its
antecedents as risk factors for Alzheimer disease (AD). Cerebral atherosclerosis or strokes may …

The Alzheimer Disease Genetics Consortium (ADGC) performed a genome-wide association
study of late-onset Alzheimer disease using a three-stage design consisting of a discovery …

Background Bapineuzumab, a humanized anti–amyloid-beta monoclonal antibody, is in
clinical development for the treatment of Alzheimer's disease. Methods We conducted two …

Background Alzheimer disease (AD) and stroke are common in elderly individuals, but the
relation between these 2 disorders remains uncertain. Objective To investigate the …

Dominantly inherited Alzheimer’s disease (DIAD) causes predictable biological changes
decades before the onset of clinical symptoms, enabling testing of interventions in the …

Background Shortening of chromosomal telomeres is a consequence of cell division and is
a biological factor related to cellular aging and potentially to more rapid organismal …